Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamps BioBOM:544312 -2.17%13 FCF Margin % is -85.72% as of Mar. 2026. GuruFocus rates BOM:544312 with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Hamps Bio ranks worse than 91.13% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hamps Bio's Free Cash Flow for the
six
months ended in Mar. 2026 was ₹-38.43 Mil. Hamps Bio's Revenue for the
six
months ended in Mar. 2026 was ₹44.83 Mil. Therefore, Hamps Bio's FCF Margin % for the quarter that ended in Mar. 2026 was -85.72%.
The historical rank and industry rank for Hamps Bio's FCF Margin % or its related term are showing as below:
BOM:544312'
s FCF Margin % Range Over the Past 10 Years
Min: -82.29 Med: -11.01 Max: 8.11
Current: -69.75
During the past 5 years, the highest FCF Margin % of Hamps Bio was 8.11%. The lowest was -82.29%. And the median was -11.01%.
BOM:544312's FCF Margin % is ranked worse than 91.13% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 3.09
vs BOM:544312: -69.75
The historical data trend for Hamps Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Hamps Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamps Bio FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hamps Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hamps Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio (BOM:544312) has a FCF Margin % of -85.72% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hamps Bio and its competitors. According to the industry distribution chart, Hamps Bio ranks #606 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 91.1%.
Is Hamps Bio's FCF Margin % too high?
Hamps Bio's current FCF Margin % is -85.72%. Based on the distribution chart, Hamps Bio ranks #606 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Hamps Bio has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's FCF Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hamps Bio ranks #606 out of 665 companies for FCF Margin %. This places Hamps Bio in the lower half of its industry. The industry median FCF Margin % is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.09, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hamps Bio and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamps Bio's current FCF Margin % is -85.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current FCF Margin % of -85.72%. The current FCF Margin % is -85.72%. Hamps Bio's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current FCF Margin % is -85.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
13GF Score
Get the complete analysis for BOM:544312
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
